Literature DB >> 27041573

Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression.

A Ellert-Miklaszewska1, P Wisniewski1, M Kijewska1, P Gajdanowicz1, D Pszczolkowska1, P Przanowski1, M Dabrowski1, M Maleszewska1, B Kaminska1.   

Abstract

Tumour tissue is infiltrated by myeloid cells that are reprogrammed into alternatively activated/regenerative (M2) macrophages. The contribution of major signalling pathways and their modulators/targets involved in the macrophage reprogramming is poorly known. Glioblastoma (malignant brain tumour) attracts and reprograms brain-resident microglia and peripheral macrophages into cells that increase invasion, angiogenesis and suppress antitumour immunity. Using a 'function-first' approach and glioma secretome proteomics we identified osteopontin and lactadherin as proteins that cooperatively activate amoeboid transformation, phagocytosis and motility of primary microglia cultures via integrins and FAK-Akt (focal adhesion kinase-Akt) signalling. A synthetic peptide interfering with integrin ligands blocks glioma-microglia communication, functional activation and M2 gene expression. We found that osteopontin/secreted phosphoprotein 1 (Spp1) produced by non-transformed cells acts as a proinflammatory factor inducing inflammatory signalling and M1 genes, and counteracts the action of lactadherin. Using constructs encoding functional mutants of osteopontin, we demonstrated sequential processing of Spp1 by thrombin and matrix metalloproteinase-3 and/or -7 (MMP-3 and/or -7) in glioma cells, which generates a microglia-activating form devoid of the inflammatory activity, while retaining the M2 reprogramming potential. A similar form of osteopontin is secreted by human glioma cells but not normal human astrocytes. Knockdown of osteopontin or lactadherin in glioma cells reduces intracranial glioma growth, blocks amoeboid transformation of myeloid cells and affects M2 reprogramming of microglia/macrophages. Our findings demonstrate how glioma cells misuse macrophage-activating signals and redesign primarily proinflammatory signals towards their advantage to induce M2 reprogramming of tumour-infiltrating brain macrophages.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27041573     DOI: 10.1038/onc.2016.55

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology.

Authors:  Oscar M Pello; Maria De Pizzol; Massimiliano Mirolo; Laura Soucek; Luca Zammataro; Angelo Amabile; Andrea Doni; Manuela Nebuloni; Lamorna B Swigart; Gerard I Evan; Alberto Mantovani; Massimo Locati
Journal:  Blood       Date:  2011-11-08       Impact factor: 22.113

2.  Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia.

Authors:  Aleksandra Ellert-Miklaszewska; Michal Dabrowski; Maciej Lipko; Marcin Sliwa; Marta Maleszewska; Bozena Kaminska
Journal:  Glia       Date:  2013-05-07       Impact factor: 7.452

3.  Identification of a factor that links apoptotic cells to phagocytes.

Authors:  Rikinari Hanayama; Masato Tanaka; Keiko Miwa; Azusa Shinohara; Akihiro Iwamatsu; Shigekazu Nagata
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

4.  Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment.

Authors:  Zhifei Shao; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

5.  Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin).

Authors:  R Agnihotri; H C Crawford; H Haro; L M Matrisian; M C Havrda; L Liaw
Journal:  J Biol Chem       Date:  2001-05-25       Impact factor: 5.157

6.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

7.  CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs).

Authors:  Janka Held-Feindt; Kirsten Hattermann; Susanne Sebens Müerköster; Hanna Wedderkopp; Friederike Knerlich-Lukoschus; Hendrik Ungefroren; H Maximilian Mehdorn; Rolf Mentlein
Journal:  Exp Cell Res       Date:  2010-02-23       Impact factor: 3.905

8.  Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas.

Authors:  Michael Platten; Alexandra Kretz; Ulrike Naumann; Steffen Aulwurm; Kensuke Egashira; Stefan Isenmann; Michael Weller
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

9.  Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

Authors:  Y Komohara; K Ohnishi; J Kuratsu; M Takeya
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

10.  Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.

Authors:  Wenchao Zhou; Susan Q Ke; Zhi Huang; William Flavahan; Xiaoguang Fang; Jeremy Paul; Ling Wu; Andrew E Sloan; Roger E McLendon; Xiaoxia Li; Jeremy N Rich; Shideng Bao
Journal:  Nat Cell Biol       Date:  2015-01-12       Impact factor: 28.824

View more
  33 in total

Review 1.  The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics.

Authors:  Kimberly Ann Rivera-Caraballo; Mitra Nair; Tae Jin Lee; Balveen Kaur; Ji Young Yoo
Journal:  Mol Ther Oncolytics       Date:  2022-06-06       Impact factor: 6.311

Review 2.  Pineal Gland Tumor Microenvironment.

Authors:  Joham Choque-Velasquez; Szymon Baluszek; Roberto Colasanti; Sajjad Muhammad; Juha Hernesniemi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.

Authors:  Frank Szulzewsky; Nina Schwendinger; Dilansu Güneykaya; Patrick J Cimino; Dolores Hambardzumyan; Michael Synowitz; Eric C Holland; Helmut Kettenmann
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

4.  Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma.

Authors:  Peiwen Chen; Di Zhao; Jun Li; Xin Liang; Jiexi Li; Andrew Chang; Verlene K Henry; Zhengdao Lan; Denise J Spring; Ganesh Rao; Y Alan Wang; Ronald A DePinho
Journal:  Cancer Cell       Date:  2019-06-10       Impact factor: 31.743

5.  JAM-A functions as a female microglial tumor suppressor in glioblastoma.

Authors:  Soumya M Turaga; Daniel J Silver; Defne Bayik; Evi Paouri; Sen Peng; Adam Lauko; Tyler J Alban; Nozha Borjini; Sarah Stanko; Ulhas P Naik; Ruth A Keri; James R Connor; Jill S Barnholtz-Sloan; Joshua B Rubin; Michael Berens; Dimitrios Davalos; Justin D Lathia
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

6.  Thrombin cleavage of osteopontin initiates osteopontin's tumor-promoting activity.

Authors:  Sameera Peraramelli; Qi Zhou; Qin Zhou; Bettina Wanko; Lei Zhao; Toshihiko Nishimura; Thomas H Leung; Seiya Mizuno; Mamoru Ito; Timothy Myles; Thomas M Stulnig; John Morser; Lawrence L K Leung
Journal:  J Thromb Haemost       Date:  2022-02-16       Impact factor: 16.036

Review 7.  Myeloid-derived suppressor cells in gliomas.

Authors:  Anna Gieryng; Bozena Kaminska
Journal:  Contemp Oncol (Pozn)       Date:  2016-12-20

8.  Osteopontin Peptide Icosamer Containing RGD and SLAYGLR Motifs Enhances the Motility and Phagocytic Activity of Microglia.

Authors:  Il-Doo Kim; Hahnbie Lee; Yin-Chuan Jin; Ja-Kyeong Lee
Journal:  Exp Neurobiol       Date:  2017-12-11       Impact factor: 3.261

Review 9.  Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.

Authors:  Jun Ma; Clark C Chen; Ming Li
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 10.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.